Cullinan Therapeutics and Taiho Oncology have unveiled phase 3 data for their tyrosine kinase inhibitor (TKI) that could challenge Johnson & Johnson’s Rybrevant for patients with advanced non-small ...
GE HealthCare is said to be on the cusp of buying out radiopharmaceutical developer Sofie Biosciences, according to a report by the Financial Times. | GE HealthCare is said to be on the cusp of buying ...
GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3 trial, painting ...
The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor zanzalintinib in combination with Roche’s ...
Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. | ...
The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
The 5-star Raffles Hotel in Boston was a fitting location for the launch of Singapore’s fifth international hub in the U.S., ...
MelliCell CEO Ben Pope, Ph.D., echoed the need for increased access to funds. The Greater Boston-based biotech company has a ...
The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from ...
Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results